CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $50.27, demonstrating a +1.68% change from the preceding day's closing price. This move lagged the S&P 500's daily gain of 1.75%. Elsewhere, the Dow saw an upswing of 1.86%, while the tech-heavy Nasdaq appreciated by 2.54%. Heading into today, shares of the company had lost 6.27% over the past month, lagging the Medical sector's gain of 3.73% and the S&P 500's loss of 1.63%.The investment community will be paying close attention to the earnings performance of CRISPR Therapeutics AG in its upcoming release. The company is expected to report EPS of -$1.11, up 13.95% from the prior-year quarter. In the meantime, our current consensus estimate forecasts the revenue to be $9.28 million, indicating a 942.7% growth compared to the corresponding quarter of the prior year. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$4.9 per share and revenue of $38.88 million, indicating changes of +24.27% and +1007.58%, respectively, compared to the previous year. It is also important to note the recent changes to analyst estimates for CRISPR Therapeutics AG. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 3.99% higher within the past month. CRISPR Therapeutics AG is currently sporting a Zacks Rank of #3 (Hold). The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 153, positioning it in the bottom 38% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks